In a world inundated with terms like ‘alternate facts’ and ‘post truth’ we take comfort in numbers.
Our business is simple, you make money for your clients or you don’t. No amount of academic accreditations, algorithms or excuses can compensate for not making successful investment decisions (see ‘Long Term Capital Management’…).
Here is how major asset classes performed in January:
To translate: our overweights in tech, emerging markets, and biotech delivered exceptional results in our equity allocations.
Our average weighted returns for January will be available shortly. January seems to have gone on forever, but it was nevertheless a good month for our client portfolios.